Latest Information Update: 29 Sep 1997
At a glance
- Originator LEK
- Class Dipeptides
- Mechanism of Action Peptide stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 29 Sep 1997 Discontinued-Preclinical for Cancer in Slovenia (Unknown route)
- 16 Apr 1997 No-Development-Reported for Cancer in Slovenia (Unknown route)